Journals / Dicle Tıp Dergisi / 2016 / Cilt: 43 - Sayı: 1

An Ischemic Stroke Related to Eltrombopag Use in a Patient with Idiopathic Thrombocytopenic Purpura

İdiopatik Trombositopenik Purpuralı Bir Olguda Eltrombopag Kullanımı ile İlişkili İskemik İnme

Pages
171–173
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Because of this rare seen situation, it was argued by in the light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thrombopoetin receptor agonists like eltrombopag, used for Idiopathic Thrombocytopenic Purpura treatment rarely cause to the ischemic cerebrovascular disease.
📊
Key Findings & Data:In this re- port, a patient, have been followed by ITP diagnosis for 5 years, admitted to the emergency service for right hemi- paresis and aphasia.
💡
Conclusion & Impact:Because of this rare seen situation, it was argued by in the light of the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Thrombopoetin receptor agonists like eltrombopag, used for Idiopathic Thrombocytopenic Purpura treatment rarely cause to the ischemic cerebrovascular disease. In this re- port, a patient, have been followed by ITP diagnosis for 5 years, admitted to the emergency service for right hemi- paresis and aphasia. It was diagnosed as ischemic cere- brovascular disease. Etiology of patient’s cerebrovascu- lar event was associated with eltrombopag. Because of this rare seen situation, it was argued by in the light of the literature.

Özet

Idiopatik trombositopenik purpura (ITP) tedavisinde kul- lanılmakta olan eltrombopag gibi trombopoetin reseptör (TpoR) agonistlerinin iskemik serebrovasküler hastalık oluşturma riski nadir görülmektedir. 5 yıldır ITP tanısı ile takip edilen sağ hemiparezi ve afazi kliniği ile acil servi- se başvuran hastaya yapılan tetkikler sonucunda iskemik serebrovasküler hastalık tanısı konuldu. Olguda serebro- vasküler hastalığın etyolojisi eltrombopag ile ilişkilendiril- di. Bu olgunun nadir görülmesi nedeniyle literatür eşliğin- de tartışıldı.

🔖

Cite This Article

ARSLAN, D., KELKİTLİ, E. (2016). An Ischemic Stroke Related to Eltrombopag Use in a Patient with Idiopathic Thrombocytopenic Purpura. Dicle Tıp Dergisi, Cilt: 43 - Sayı: 1, 171–173. https://ajindex.com/articles/203596

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Chen YC, Wu JS, Yang ST, et al. Stroke, angiogenesis and phytochemicals. Front Biosci 2012; 4:599-610
  2. Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New Engl J Med 2007; 357:2237-2247
  3. Park HK, Lee SH. Ischemic stroke associated with immune thrombocytopenia: lesion patterns and characteristics. Neu- rol Sci 2014; 35:1801-1806 4. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune throm- bocytopenia in the United Kingdom General Practice Re- search Database. Haematologica 2010; 95:1167-1175
  4. Aoki T, Harada Y, Matsubara E, et al. Thrombopoietin recep- tor agonists in refractory immune thrombocytopenia: dif- ferential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Theraps 2012; 37:729-732
  5. Norgaard M: Thrombosis in patients with primary chronic immune thrombocytopenia. Thrombosis research. 2012; 130:74-75
  6. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin recep- tor agonist. Blood 2007; 109:4739-4741
  7. Catala-Lopez F, Corrales I, Martin-Serrano G, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin 2012; 139:421-429
  8. Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109:676-683
  9. Andic N, Gunduz E, Akay OM, et al. Cardiac and pulmo- nary thrombosis during multidrug treatment in an idio- pathic thrombocytopenic purpura patient. Platelets 2014; 25:69-70 11. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393-402
  10. Tomiyama Y, Miyakawa Y, Okamoto S, et al: A lower start- ing dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10:799-806.